Evercore ISI analyst Vijay Kumar raised the firm’s price target on Illumina (ILMN) to $155 from $142 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $144 from $114 at Guggenheim
- Illumina price target raised to $130 from $112 at Canaccord
- Illumina price target raised to $130 from $105 at JPMorgan
- Illumina price target raised to $110 from $100 at Barclays
- Illumina, MyOme announces collaboration, investment by Illumina into MyOme